CIK 0001563577
GRTX Galera Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Nov 24, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at Galera Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | Mel Sorensen President and CEO sell | $1,407 70,000 shares | -26% | - | |
| 41Moderate | Nancy T Chang director, owner buy | $500k 7,644,932 shares | - | - |
Transactions
The last 10 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | Mel Sorensen President and CEO | SOpen-market sale Common Stock | -70,000 | $0.02 | $1,407 | 195,029 | Nov 24, 2025 |
| May 1, 2025 | Mel Sorensen President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +6,000,000 | $0.00 | $0 | 6,000,000 | May 5, 2025 |
| May 1, 2025 | Joel F. Sussman Chief Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | May 5, 2025 |
| Feb 24, 2025 | Lawrence M Alleva director | AGrant or award Stock Option (Right to Buy)derivative | +48,000 | $0.00 | $0 | 48,000 | Feb 26, 2025 |
| Feb 24, 2025 | Nancy T Chang director, owner | AGrant or award Stock Option (Right to Buy)derivative | +96,000 | $0.00 | $0 | 96,000 | Feb 26, 2025 |
| Feb 24, 2025 | Michael R. Friedman director | AGrant or award Stock Option (Right to Buy)derivative | +96,000 | $0.00 | $0 | 96,000 | Feb 26, 2025 |
| Feb 24, 2025 | Kevin G Lokay director | AGrant or award Stock Option (Right to Buy)derivative | +48,000 | $0.00 | $0 | 48,000 | Feb 26, 2025 |
| Dec 30, 2024 | Nancy T Chang director, owner | POpen-market purchase Common Stock | +7,644,932 | $0.07 | $500k | 7,644,932 | Jan 2, 2025 |
| Dec 30, 2024 | Michael R. Friedman director | AGrant or award Series B Preferred Stockderivativeindirect: See Footnote | +8,326 | $0.00 | $0 | 8,326 | Jan 2, 2025 |
| Dec 30, 2024 | Nancy T Chang director, owner | AGrant or award Series B Preferred Stockderivative | +1,842 | $0.00 | $0 | 1,842 | Jan 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Lawrence M Allevadirector
- Nancy T Changdirector, owner
- Michael R. Friedmandirector
- Kevin G Lokaydirector
- Mel SorensenPresident and CEO
- Joel F. SussmanChief Accounting Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.